Differential effects of α4β7 and GPR15 on homing of effector and regulatory T cells from patients with UC to the inflamed gut in vivo.

Current and emerging therapeutic targets for IBD. Nat Rev Gastroenterol Hepatol (2017) 1.42

Leukocyte Trafficking to the Small Intestine and Colon. Gastroenterology (2015) 0.85

Differential expression of GPR15 on T cells during ulcerative colitis. JCI Insight (2017) 0.78

AHR Activation Is Protective against Colitis Driven by T Cells in Humanized Mice. Cell Rep (2016) 0.78

Insulin resistance in vascular endothelial cells promotes intestinal tumour formation. Oncogene (2017) 0.75

Increased tumor-infiltrating CD45RA(-)CCR7(-) regulatory T-cell subset with immunosuppressive properties foster gastric cancer progress. Cell Death Dis (2017) 0.75

Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat Rev Immunol (2007) 17.18

Humanized mice in translational biomedical research. Nat Rev Immunol (2007) 8.83

Chemically induced mouse models of intestinal inflammation. Nat Protoc (2007) 8.65

The microbiology of butyrate formation in the human colon. FEMS Microbiol Lett (2002) 7.29

The fundamental basis of inflammatory bowel disease. J Clin Invest (2007) 6.84

Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo. Nat Med (2000) 6.68

Natalizumab for active Crohn's disease. N Engl J Med (2003) 6.44

Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med (2005) 6.33

Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med (2005) 5.36

Immunity, inflammation, and allergy in the gut. Science (2005) 4.82

Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med (2013) 4.75

Crohn's disease. Lancet (2012) 4.42

Role of alpha 4-integrins in lymphocyte homing to mucosal tissues in vivo. J Immunol (1994) 4.21

Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med (2013) 3.98

Cytokines in inflammatory bowel disease. Nat Rev Immunol (2014) 3.24

Safety and efficacy of antigen-specific regulatory T-cell therapy for patients with refractory Crohn's disease. Gastroenterology (2012) 2.95

Antigen receptor engagement delivers a stop signal to migrating T lymphocytes. Proc Natl Acad Sci U S A (1997) 2.89

Peripheral and intestinal regulatory CD4+ CD25(high) T cells in inflammatory bowel disease. Gastroenterology (2005) 2.78

Breaching multiple barriers: leukocyte motility through venular walls and the interstitium. Nat Rev Mol Cell Biol (2010) 2.72

TH9 cells that express the transcription factor PU.1 drive T cell-mediated colitis via IL-9 receptor signaling in intestinal epithelial cells. Nat Immunol (2014) 2.62

Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial. Lancet (2014) 2.61

Transforming growth factor beta induced FoxP3+ regulatory T cells suppress Th1 mediated experimental colitis. Gut (2005) 2.37

Expression of transforming growth factors alpha and beta in colonic mucosa in inflammatory bowel disease. Gastroenterology (1996) 2.01

A fundamental subdivision of circulating lymphocytes defined by adhesion to mucosal addressin cell adhesion molecule-1. Comparison with vascular cell adhesion molecule-1 and correlation with beta 7 integrins and memory differentiation. J Immunol (1996) 1.92

Monoclonal antibodies specific for beta 7 integrin and mucosal addressin cell adhesion molecule-1 (MAdCAM-1) reduce inflammation in the colon of scid mice reconstituted with CD45RBhigh CD4+ T cells. J Immunol (1997) 1.89

New therapies for inflammatory bowel disease: from the bench to the bedside. Gut (2011) 1.84

Rapid resolution of chronic colitis in the cotton-top tamarin with an antibody to a gut-homing integrin alpha 4 beta 7. Gastroenterology (1996) 1.74

Vedolizumab affects antibody responses to immunisation selectively in the gastrointestinal tract: randomised controlled trial results. Gut (2014) 1.73

A randomised phase I study of etrolizumab (rhuMAb β7) in moderate to severe ulcerative colitis. Gut (2012) 1.73

Tissue-tropic effector T cells: generation and targeting opportunities. Nat Rev Immunol (2006) 1.59

GPR15-mediated homing controls immune homeostasis in the large intestine mucosa. Science (2013) 1.58

Role and species-specific expression of colon T cell homing receptor GPR15 in colitis. Nat Immunol (2014) 1.58

β7 integrins are required to give rise to intestinal mononuclear phagocytes with tolerogenic potential. Gut (2013) 1.49

Attenuation of colitis in the cotton-top tamarin by anti-alpha 4 integrin monoclonal antibody. J Clin Invest (1993) 1.48

CCR9-positive lymphocytes and thymus-expressed chemokine distinguish small bowel from colonic Crohn's disease. Gastroenterology (2001) 1.48

New targets for mucosal healing and therapy in inflammatory bowel diseases. Mucosal Immunol (2013) 1.25

Targeting leukocyte migration and adhesion in Crohn's disease and ulcerative colitis. Inflammopharmacology (2011) 1.24

The role of IL-13 and NK T cells in experimental and human ulcerative colitis. Mucosal Immunol (2008) 1.18

P-selectin and P-selectin glycoprotein ligand 1 are major determinants for Th1 cell recruitment to nonlymphoid effector sites in the intestinal lamina propria. J Exp Med (2003) 1.15

In vivo demonstration of T lymphocyte migration and amelioration of ileitis in intestinal mucosa of SAMP1/Yit mice by the inhibition of MAdCAM-1. Clin Exp Immunol (2005) 1.13

Vedolizumab for the treatment of IBD: a selective therapeutic approach targeting pathogenic a4b7 cells. Curr Drug Targets (2013) 1.11

Reciprocal changes of Foxp3 expression in blood and intestinal mucosa in IBD patients responding to infliximab. Inflamm Bowel Dis (2010) 1.10

Structure-function analysis of the integrin beta 7 subunit: identification of domains involved in adhesion to MAdCAM-1. J Immunol (1997) 1.10

Leukocyte migration in the interstitial space of non-lymphoid organs. Nat Rev Immunol (2014) 1.05

Accumulation of CCR5+ T cells around RANTES+ granulomas in Crohn's disease: a pivotal site of Th1-shifted immune response? Lab Invest (2005) 1.04

In vivo imaging of T-cell motility in the elicitation phase of contact hypersensitivity using two-photon microscopy. J Invest Dermatol (2011) 0.97

Expression of CD4+ forkhead box P3 (FOXP3)+ regulatory T cells in inflammatory bowel disease. J Dig Dis (2011) 0.97

Developing in vitro expanded CD45RA+ regulatory T cells as an adoptive cell therapy for Crohn's disease. Gut (2015) 0.92

Homeostatic (IL-7) and effector (IL-17) cytokines as distinct but complementary target for an optimal therapeutic strategy in inflammatory bowel disease. Curr Opin Gastroenterol (2009) 0.90

An integrin alpha4beta7•IgG heterodimeric chimera binds to MAdCAM-1 on high endothelial venules in gut-associated lymphoid tissue. J Histochem Cytochem (2011) 0.77

α4β7 integrin: beyond T cell trafficking. Gut (2013) 0.77

In vitro assessment of the effects of vedolizumab binding on peripheral blood lymphocytes. MAbs (2014) 0.77

E-cadherin can limit the transforming properties of activating β-catenin mutations. EMBO J (2015) 0.94

Immunopathogenesis of inflammatory bowel diseases: functional role of T cells and T cell homing. Clin Exp Rheumatol (2015) 0.77

Novel Insights into the Mechanisms of Gut Homing and Antiadhesion Therapies in Inflammatory Bowel Diseases. Inflamm Bowel Dis (2017) 0.76

Blockade of αEβ7 integrin suppresses accumulation of CD8(+) and Th9 lymphocytes from patients with IBD in the inflamed gut in vivo. Gut (2016) 0.75

Pathogenic T cell subsets in allergic and chronic inflammatory bowel disorders. Immunol Rev (2017) 0.75

Utilization of Diagnostic Imaging and Ionizing Radiation Exposure-Has the Tide Already Turned? Inflamm Bowel Dis (2019) 0.75

Block Excision of Iridociliary Tumors Enables Molecular Profiling and Immune Vaccination. Ophthalmology (2016) 0.75